Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial

From the Lancet this week:

More bad news from the WHI - Women had a trend (NS) towards more NSCLC diagnoses in the HRT arm, and statistically significant worse survival from lung cancer. Of course this is post-hoc, and should be treated as hypothesis generating more than definitive evidence. Regardless, enthusiasm for HRT has been sufficiently curbed.

Link:

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial: "In the post-intervention period of the Women's Health Initiative (WHI) trial, women assigned to treatment with oestrogen plus progestin had a higher risk of cancer than did those assigned to placebo. Results also suggested that the combined hormone therapy might increase mortality from lung cancer. To assess whether such an association exists, we undertook a post-hoc analysis of lung cancers diagnosed in the trial over the entire follow-up period."